Charles River Laboratories International, Inc. (CRL)
International Markets and Charles River (CRL): A Deep Dive for Investors
Explore how Charles River's (CRL) revenue from international markets is changing and the resulting impact on Wall Street's predictions and the stock's prospects.
Charles River Laboratories International Q2 Earnings Call Highlights
Charles River Laboratories International NYSE: CRL reported second-quarter results that exceeded its prior outlook, citing improved demand in its Discovery and Safety Assessment, or DSA, business and stronger-than-expected manufacturing performance. The company raised its full-year revenue, earnings and free-cash-flow guidance while maintaining a cautious view that the recovery in biopharmaceutical demand will progress gradually.
CRL Q2 Earnings and Revenues Top, '26 View Up, Stock Up in Pre-Market
Charles River beats Q2 earnings and revenue estimates, raises 2026 outlook and gains 7.9% in pre-market trading.
Has Charles River Laboratories International (CRL) Outpaced Other Medical Stocks This Year?
Here is how Charles River Laboratories (CRL) and Curaleaf Holdings, Inc. (CURLF) have performed compared to their sector so far this year.
Charles River: Near-Term Inflection But Long-Term Risk
Charles River Laboratories has rebounded 40% from last year, driven by improved organic revenue and a positive inflection in order trends. CRL raised guidance, now expecting slightly positive organic growth and EPS of $11.15–$11.45, with margin expansion locked in through divestitures and cost cuts. Segment performance is mixed: DSA shows strong backlog and book-to-bill, while RMS faces U.S. weakness offset by China strength; manufacturing margins benefit from divestitures.
Charles River (CRL) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for Charles River (CRL) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Charles River Laboratories (CRL) Q2 Earnings and Revenues Surpass Estimates
Charles River Laboratories (CRL) came out with quarterly earnings of $3.02 per share, beating the Zacks Consensus Estimate of $2.72 per share. This compares to earnings of $3.12 per share a year ago.
Charles River Prepares to Report Q2 Earnings: What's in Store?
CRL is set to report Q2 results on Aug. 5 as investors watch segment demand, divestitures, and whether the company can extend its earnings beat streak.
Charles River Laboratories (CRL) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
Charles River (CRL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
What Makes Charles River Laboratories (CRL) a Strong Momentum Stock: Buy Now?
Does Charles River Laboratories (CRL) have what it takes to be a top stock pick for momentum investors? Let's find out.
Will Charles River (CRL) Beat Estimates Again in Its Next Earnings Report?
Charles River (CRL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
LH or CRL: Which Is the Better Value Stock Right Now?
Investors with an interest in Medical Services stocks have likely encountered both Labcorp Holdings (LH) and Charles River Laboratories (CRL). But which of these two companies is the best option for those looking for undervalued stocks?
